Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    Pulmonary Embolism | Open Studies | NIH, U.S. Fed
Show Display Options
RSS Create an RSS feed from your search for:
Pulmonary Embolism | Open Studies | NIH, U.S. Fed
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
Conditions: Venous Thromboembolism;   Deep Venous Thrombosis;   Pulmonary Embolus
Interventions: Drug: Twice daily enoxaparin prophylaxis;   Drug: Real time dose adjustment
2 Recruiting Nitric Oxide to Treat Pulmonary Embolism
Condition: Pulmonary Embolism
Interventions: Drug: Nitric Oxide + oxygen;   Drug: Nitrogen + Oxygen
3 Recruiting Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
Conditions: Chronic Kidney Disease;   Pulmonary Embolism;   Renal Artery Stenosis;   Pulmonary Cancer
Interventions: Drug: Low Volume iso-osmolar non-ionic radio contrast medium;   Drug: Acetylcysteine Inhalation;   Drug: Sodium Bicarbonate Solution;   Procedure: 64-MDCT Scanning
4 Recruiting Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults
Condition: HIV
Intervention:
5 Recruiting Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Conditions: Deep Vein Thrombosis;   Malignant Neoplasm;   Portal Vein Thrombosis;   Pulmonary Embolism;   Renal Vein Thrombosis;   Venous Thromboembolism
Interventions: Drug: Apixaban;   Drug: Dalteparin;   Other: Questionnaire Administration
6 Recruiting A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
Conditions: Atrial Fibrillation;   Deep Vein Thrombosis;   Cardiac Valvular Insufficiency;   Coagulopathies;   Pulmonary Embolism
Interventions: Genetic: Genotype-guided;   Other: Standard-of-Care
7 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
8 Recruiting A Randomized Trial of Induction Versus Expectant Management
Condition: Labor and Delivery
Intervention: Procedure: Elective Induction of Labor
9 Recruiting Prehospital Tranexamic Acid Use for Traumatic Brain Injury
Condition: Traumatic Brain Injury
Interventions: Drug: 1 gram Tranexamic Acid (TXA);   Drug: 2 grams TXA;   Drug: 0.9% Sodium Chloride injectable
10 Recruiting Cancer Associated Thrombosis and Isoquercetin (CAT IQ)
Conditions: Thromboembolism of Vein VTE in Colorectal Cancer;   Thromboembolism of Vein in Pancreatic Cancer;   Thromboembolism of Vein in Non-small Cell Lung Cancer
Intervention: Drug: Isoquercetin
11 Recruiting Patient-Centered Anticoagulation Self-Monitoring in Minority Patients
Conditions: Thromboembolism;   Blood Coagulation Disorders;   Cardiovascular Disease;   Vascular Disease
Intervention: Other: Patient Self-Monitoring vs Anticoagulation Clinic
12 Recruiting Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus
Conditions: Thrombosis;   Type 2 Diabetes Mellitus
Interventions: Dietary Supplement: Primrose oil;   Dietary Supplement: Fish Oil
13 Recruiting Fatty Acid Regulation of Platelet Function in Diabetes
Conditions: Thrombosis;   Type 2 Diabetes Mellitus
Intervention: Other: omega-3 and -6 fatty acids and their 12-LOX oxylipins
14 Not yet recruiting Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial
Conditions: Deep Vein Thrombosis;   Post-Thrombotic Syndrome;   Venous Thrombosis
Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA);   Drug: Standard Anticoagulation Therapy
15 Recruiting Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Condition: Thromboembolism
Interventions: Genetic: Pharmacogenetic;   Drug: Target INR 1.8

Study has passed its completion date and status has not been verified in more than two years.